Healthcare professionals

Welcome

Links

Explore more information about allergy immunotherapy (AIT) and its long-term disease-modifying and protective effects, ALK’s movement from experience- to evidence-based AIT with clinical trials and real-world evidence, and our compliance with guidelines and sharing of clinical data. All collected for you as a healthcare professional with the purpose of improving understanding of allergic disease, assisting prescriber decisions, and helping more people living with allergy.

Also, we present the Henning Løwenstein Research Award – an award to young scientists who has shown excellence within the field of allergy.

Allergy immunotherapy

AIT is the only treatment targeting the root cause of allergy – the immune system. Therefore, AIT has not only the capacity of improving symptoms and reducing the need for other medication, but also to induce specific tolerance beyond the duration of treatment, modify the course of the disease, and prevent development of new sensitisations and co-morbidities.

Learn more

Our data

In ALK, we focus on expanding the access to evidence-based AIT. We commit to investigating the safety and efficacy of specific treatment in controlled settings – clinical trials – and in uncontrolled settings – the real-world, where factors that may influence the outcomes are included. This commitment offers the best of two worlds, assisting prescribers in treatment decisions and helping people living with allergy.

Learn more

Henning Løwenstein Research Award

The Henning Løwenstein Research Award was established and dedicated to researcher Henning Løwenstein by ALK on his 25th anniversary of at the company. This biennial award is given to a young scientist who has shown excellence within the field of allergy research.

Learn more